|
US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
|
US7544511B2
(en)
*
|
1996-09-25 |
2009-06-09 |
Neuralstem Biopharmaceuticals Ltd. |
Stable neural stem cell line methods
|
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
|
CZ20012358A3
(cs)
*
|
1998-12-31 |
2002-01-16 |
Societe De Conseils De Recherches Et D´Application |
Prenyltransferázové inhibitory
|
|
AU2002344820B2
(en)
|
2001-06-20 |
2006-12-14 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
CA2450475A1
(en)
|
2001-06-20 |
2003-01-03 |
Linda Brockunier |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
JP3909056B2
(ja)
|
2001-06-27 |
2007-04-25 |
スミスクライン ビーチャム コーポレーション |
ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
|
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
|
WO2003068805A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Formulation strategies in stabilizing peptides in organic solvents and in dried states
|
|
WO2003082817A2
(en)
|
2002-03-25 |
2003-10-09 |
Merck & Co., Inc. |
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
US7208498B2
(en)
*
|
2002-07-15 |
2007-04-24 |
Merck & Co., Inc. |
Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
AU2003275404A1
(en)
*
|
2002-10-07 |
2004-05-04 |
Merck & Co., Inc. |
Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
|
|
BR0315381A
(pt)
*
|
2002-10-18 |
2005-08-23 |
Merck & Co Inc |
Composto ou um sal farmaceuticamente aceitável deste, composição farmacêutica, e, métodos para inibir a atividade da enzima dipeptidil peptidase-iv em um mamìfero em necessidade disto, para tratar diabetes em um mamìfero em necessidade disto, para tratar diabete não dependente de insulina (tipo 2) em um mamìfero em necessidade disto, para tratar hiperglicemia em um mamìfero em necessidade disto, para tratar a obesidade em um mamìfero em necessidade disto, para tratar um ou mais distúrbios de lipìdios selecionados do grupo de dislipidemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, hdl baixo e ldl alto em um mamìfero em necessidade disto, e para tratar em um mamìfero em necessidade disto uma ou mais condições
|
|
ES2278213T3
(es)
|
2002-11-07 |
2007-08-01 |
MERCK & CO., INC. |
Derivados de fenilamina como inhibidores de la dipeptidilpeptidasa en el tratamiento o la prevencion de la diabetes.
|
|
US7309714B2
(en)
*
|
2002-12-04 |
2007-12-18 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
US20040185429A1
(en)
|
2002-12-09 |
2004-09-23 |
Judith Kelleher-Andersson |
Method for discovering neurogenic agents
|
|
US8293488B2
(en)
|
2002-12-09 |
2012-10-23 |
Neuralstem, Inc. |
Method for screening neurogenic agents
|
|
EP1572196B1
(en)
*
|
2002-12-10 |
2008-08-13 |
Novartis AG |
Combination of a dpp-iv inhibitor and a ppar-alpha compound
|
|
CA2508947A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
NZ540612A
(en)
|
2003-01-14 |
2008-02-29 |
Arena Pharm Inc |
1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
|
EP1589969A4
(en)
*
|
2003-01-17 |
2008-08-13 |
Merck & Co Inc |
3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
EP1592689A4
(en)
*
|
2003-01-31 |
2008-12-24 |
Merck & Co Inc |
3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
|
|
AR043443A1
(es)
*
|
2003-03-07 |
2005-07-27 |
Merck & Co Inc |
Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
|
|
AR043505A1
(es)
*
|
2003-03-18 |
2005-08-03 |
Merck & Co Inc |
Preparacion de beta-cetoamidas e intermediarios de reaccion
|
|
AR043515A1
(es)
*
|
2003-03-19 |
2005-08-03 |
Merck & Co Inc |
Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
|
|
WO2004085661A2
(en)
*
|
2003-03-24 |
2004-10-07 |
Merck & Co., Inc |
Process to chiral beta-amino acid derivatives
|
|
EP1608317B1
(en)
|
2003-03-25 |
2012-09-26 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
WO2004087650A2
(en)
*
|
2003-03-27 |
2004-10-14 |
Merck & Co. Inc. |
Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
|
|
ZA200508439B
(en)
|
2003-05-05 |
2007-03-28 |
Probiodrug Ag |
Medical use of inhibitors of glutaminyl and glutamate cyclases
|
|
GB0310593D0
(en)
*
|
2003-05-08 |
2003-06-11 |
Leuven K U Res & Dev |
Peptidic prodrugs
|
|
EP1625122A1
(en)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
CN1787823A
(zh)
*
|
2003-05-14 |
2006-06-14 |
麦克公司 |
作为二肽基肽酶抑制剂用于治疗或预防糖尿病的3－氨基－4－苯基丁酸衍生物
|
|
CN1798556A
(zh)
*
|
2003-06-06 |
2006-07-05 |
麦克公司 |
作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
|
|
US20070099884A1
(en)
*
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
|
CA2527806A1
(en)
*
|
2003-06-17 |
2004-12-29 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
JO2625B1
(en)
*
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
MXPA06000554A
(es)
|
2003-07-14 |
2006-07-03 |
Arena Pharm Inc |
Derivados arilo y heteroarilo fusionados como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con los mismos.
|
|
ES2328579T3
(es)
*
|
2003-07-25 |
2009-11-16 |
Conjuchem Biotechnologies Inc. |
Derivados de insulina de larga duracion y procedimientos asociados.
|
|
CA2533893A1
(en)
*
|
2003-07-31 |
2005-02-10 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
DE602004010206T2
(de)
*
|
2003-08-13 |
2008-10-09 |
Takeda Pharmaceutical Co. Ltd. |
Dipeptidyl Peptidase Inhibitoren.
|
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
JP2007504230A
(ja)
*
|
2003-09-02 |
2007-03-01 |
メルク エンド カムパニー インコーポレーテッド |
ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
|
|
WO2005030751A2
(en)
*
|
2003-09-08 |
2005-04-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7790734B2
(en)
*
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
JP4765627B2
(ja)
|
2003-09-22 |
2011-09-07 |
Ｍｓｄ株式会社 |
新規ピペリジン誘導体
|
|
EP1667524A4
(en)
*
|
2003-09-23 |
2009-01-14 |
Merck & Co Inc |
NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTASE-IV INHIBITOR
|
|
US20070123470A1
(en)
*
|
2003-10-24 |
2007-05-31 |
Wladimir Hogenhuis |
Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
|
|
NZ546887A
(en)
|
2003-11-03 |
2009-04-30 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
|
US7238683B2
(en)
*
|
2003-11-04 |
2007-07-03 |
Merck & Co., Inc. |
Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
AU2004288831B2
(en)
*
|
2003-11-12 |
2010-08-26 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
|
KR20180050427A
(ko)
|
2003-11-17 |
2018-05-14 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
|
WO2005072530A1
(en)
*
|
2004-01-16 |
2005-08-11 |
Merck & Co., Inc. |
Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
|
|
ES2940341T3
(es)
|
2004-01-20 |
2023-05-05 |
Novartis Ag |
Formulación y proceso de compresión directa
|
|
AU2005210285B2
(en)
*
|
2004-02-05 |
2008-01-24 |
Kyorin Pharmaceutical Co., Ltd. |
Bicycloester derivative
|
|
AU2005210004B2
(en)
|
2004-02-05 |
2010-10-28 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
|
EP1717225A4
(en)
*
|
2004-02-18 |
2009-10-21 |
Kyorin Seiyaku Kk |
BICYCLIC AMIDE DERIVATIVES
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
CA2557275C
(en)
*
|
2004-02-27 |
2012-06-05 |
Kyorin Pharmaceutical Co., Ltd. |
Bicyclo derivative
|
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
CA2559302C
(en)
|
2004-03-15 |
2012-06-19 |
Takeda Pharmaceutical Company Limited |
6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
|
|
AU2005230864A1
(en)
|
2004-03-29 |
2005-10-20 |
Merck Sharp & Dohme Corp. |
Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
|
WO2005097127A2
(en)
|
2004-04-02 |
2005-10-20 |
Merck & Co., Inc. |
Method of treating men with metabolic and anthropometric disorders
|
|
TW200602293A
(en)
|
2004-04-05 |
2006-01-16 |
Merck & Co Inc |
Process for the preparation of enantiomerically enriched beta amino acid derivatives
|
|
US7687492B2
(en)
*
|
2004-05-04 |
2010-03-30 |
Merck Sharp & Dohme Corp. |
1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
|
JP2007538079A
(ja)
*
|
2004-05-18 |
2007-12-27 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのシクロヘキシルアラニン誘導体
|
|
WO2005118555A1
(en)
*
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
AU2005265148B2
(en)
*
|
2004-06-21 |
2011-01-20 |
Merck Sharp & Dohme Corp. |
Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
WO2006012395A2
(en)
*
|
2004-07-23 |
2006-02-02 |
Susan Marie Royalty |
Peptidase inhibitors
|
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
|
ATE472531T1
(de)
|
2004-08-06 |
2010-07-15 |
Merck Sharp & Dohme |
Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
|
|
WO2006023750A2
(en)
*
|
2004-08-23 |
2006-03-02 |
Merck & Co., Inc. |
Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
EP1782832A4
(en)
*
|
2004-08-26 |
2009-08-26 |
Takeda Pharmaceutical |
MEANS FOR THE TREATMENT OF DIABETES
|
|
AR050615A1
(es)
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
|
WO2006033848A1
(en)
*
|
2004-09-15 |
2006-03-30 |
Merck & Co., Inc. |
Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
|
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
|
EP1796669B1
(en)
|
2004-10-01 |
2010-09-22 |
Merck Sharp & Dohme Corp. |
Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
NZ554515A
(en)
*
|
2004-10-12 |
2009-12-24 |
Glenmark Pharmaceuticals Sa |
Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
IN2014CN03629A
(pl)
|
2004-11-17 |
2015-09-04 |
Neuralstem Inc |
|
|
US7872124B2
(en)
|
2004-12-21 |
2011-01-18 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
EA015382B1
(ru)
|
2005-03-08 |
2011-08-30 |
Никомед Гмбх |
Применение рофлумиласта для лечения сахарного диабета типа 2
|
|
TWI357902B
(en)
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
|
US20090306037A1
(en)
*
|
2005-05-02 |
2009-12-10 |
Merck & Co., Inc. |
Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity
|
|
ATE540950T1
(de)
*
|
2005-05-25 |
2012-01-15 |
Merck Sharp & Dohme |
Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes
|
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
ES2574014T3
(es)
|
2005-05-30 |
2016-06-14 |
Msd K.K. |
Derivado de piperidina novedoso
|
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
|
JP4915833B2
(ja)
*
|
2005-07-01 |
2012-04-11 |
雪印メグミルク株式会社 |
ジペプチジルペプチダーゼｉｖ阻害剤
|
|
WO2007015805A1
(en)
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
1-amino linked compounds
|
|
WO2007015807A1
(en)
*
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
Phenyl compounds
|
|
ES2325558T3
(es)
*
|
2005-07-20 |
2009-09-08 |
Eli Lilly And Company |
Derivados de piridina como inhibidores de dipeptidilpeptidasa.
|
|
EP1909776A2
(en)
*
|
2005-07-25 |
2008-04-16 |
Merck & Co., Inc. |
Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US20100216758A1
(en)
|
2005-08-10 |
2010-08-26 |
Makoto Ando |
Pyridone Compounds
|
|
WO2007024004A1
(ja)
|
2005-08-24 |
2007-03-01 |
Banyu Pharmaceutical Co., Ltd. |
フェニルピリドン誘導体
|
|
US7709468B2
(en)
|
2005-09-02 |
2010-05-04 |
Abbott Laboratories |
Imidazo based heterocycles
|
|
AU2006288153A1
(en)
|
2005-09-07 |
2007-03-15 |
Msd K.K. |
Bicyclic aromatic substituted pyridone derivative
|
|
NZ566797A
(en)
*
|
2005-09-14 |
2011-04-29 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors for treating diabetes
|
|
JP5027137B2
(ja)
*
|
2005-09-14 |
2012-09-19 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤の投与
|
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
|
US8222411B2
(en)
|
2005-09-16 |
2012-07-17 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
|
KR20080048502A
(ko)
|
2005-09-29 |
2008-06-02 |
머크 앤드 캄파니 인코포레이티드 |
멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
|
|
CA2625646A1
(en)
*
|
2005-10-25 |
2007-05-03 |
Merck & Co., Inc. |
Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
|
|
JPWO2007049798A1
(ja)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
新規ベンゾオキサチイン誘導体
|
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
|
CN101365432B
(zh)
|
2005-12-16 |
2011-06-22 |
默沙东公司 |
二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
|
|
EP1801098A1
(en)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
|
|
GB0526291D0
(en)
*
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
|
CA2635777A1
(en)
*
|
2005-12-28 |
2007-07-05 |
Takeda Pharmaceutical Company Limited |
Combination therapy for diabetes
|
|
AP2008004537A0
(en)
*
|
2005-12-30 |
2008-08-31 |
Ranbaxy Lab Ltd |
Muscarinic receptor antagonists
|
|
US20090156465A1
(en)
|
2005-12-30 |
2009-06-18 |
Sattigeri Jitendra A |
Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
|
|
CA2636757A1
(en)
*
|
2006-01-25 |
2007-08-02 |
Tesfaye Biftu |
Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
AU2007224066B2
(en)
*
|
2006-03-08 |
2011-10-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
|
WO2007112368A1
(en)
*
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
BRPI0709961A2
(pt)
|
2006-04-11 |
2011-08-02 |
Novartis Ag |
compostos orgánicos
|
|
JP4521838B2
(ja)
*
|
2006-04-11 |
2010-08-11 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
個体において骨質量を増加させるために有用である化合物を同定するためにｇｐｒ１１９受容体を用いる方法
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
CA2810522A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Polymorphs
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
KR20090047546A
(ko)
|
2006-09-07 |
2009-05-12 |
니코메드 게엠베하 |
당뇨병을 위한 조합 치료
|
|
KR20090088854A
(ko)
*
|
2006-09-13 |
2009-08-20 |
다케다 야쿠힌 고교 가부시키가이샤 |
2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
|
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US20090247560A1
(en)
|
2006-09-28 |
2009-10-01 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
WO2008055945A1
(en)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
DK2091948T3
(da)
|
2006-11-30 |
2012-07-23 |
Probiodrug Ag |
Nye inhibitorer af glutaminylcyclase
|
|
EP1935420A1
(en)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
|
|
KR20080071476A
(ko)
*
|
2007-01-30 |
2008-08-04 |
주식회사 엘지생명과학 |
신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
|
|
TW201350143A
(zh)
*
|
2007-02-01 |
2013-12-16 |
Takeda Pharmaceutical |
固體型製劑
|
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
JPWO2008114857A1
(ja)
*
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
|
KR101361427B1
(ko)
|
2007-04-03 |
2014-02-10 |
미쓰비시 타나베 파마 코퍼레이션 |
디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용
|
|
DK2142514T3
(da)
|
2007-04-18 |
2015-03-23 |
Probiodrug Ag |
Thioureaderivater som glutaminylcyclase-inhibitorer
|
|
US8338458B2
(en)
|
2007-05-07 |
2012-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
WO2008141021A1
(en)
*
|
2007-05-08 |
2008-11-20 |
Concert Pharmaceuticals, Inc. |
Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
EA201401193A1
(ru)
|
2007-06-04 |
2015-08-31 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Триарильные соединения и композиции, их содержащие
|
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CN101318922B
(zh)
*
|
2007-06-08 |
2010-11-10 |
上海阳帆医药科技有限公司 |
一类二肽基肽酶抑制剂、合成方法和用途
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
CA2696579C
(en)
*
|
2007-08-17 |
2017-01-24 |
Boehringer Ingelheim International Gmbh |
Purine derivatives for use in the treatment of fab-related diseases
|
|
CN101397300B
(zh)
*
|
2007-09-04 |
2011-04-27 |
山东轩竹医药科技有限公司 |
二肽酶-ⅳ抑制剂衍生物
|
|
US20090076013A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched sitagliptin
|
|
CN101417999A
(zh)
*
|
2007-10-25 |
2009-04-29 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
|
WO2009084024A2
(en)
*
|
2007-11-02 |
2009-07-09 |
Glenmark Generics Limited |
A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
|
|
US20090192326A1
(en)
*
|
2007-11-13 |
2009-07-30 |
Nurit Perlman |
Preparation of sitagliptin intermediate
|
|
CA2707790C
(en)
*
|
2007-12-20 |
2015-04-21 |
Dr. Reddy's Laboratories Limited |
Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
|
|
CA2710109C
(en)
*
|
2007-12-21 |
2016-07-19 |
Lg Life Sciences Ltd. |
Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
|
|
CN101468988A
(zh)
|
2007-12-26 |
2009-07-01 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
AP2010005364A0
(en)
*
|
2008-01-24 |
2010-08-31 |
Panacea Biotec Ltd |
Novel heterocyclic compounds.
|
|
CA2713361A1
(en)
*
|
2008-02-05 |
2009-08-13 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
|
MX2010009731A
(es)
*
|
2008-03-04 |
2010-09-30 |
Merck Sharp & Dohme |
Composiciones farmaceuticas de una combinacion de metformina y un inhibidor de dipeptidil peptidasa-iv.
|
|
AU2009220605A1
(en)
|
2008-03-06 |
2009-09-11 |
Msd K.K. |
Alkylaminopyridine derivative
|
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
|
CA2717384A1
(en)
|
2008-03-28 |
2009-10-01 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
|
US20090247532A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Mae De Ltd. |
Crystalline polymorph of sitagliptin phosphate and its preparation
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
EP2146210A1
(en)
*
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
|
US20090264476A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Mckelvey Craig |
CB-1 receptor modulator formulations
|
|
US8003672B2
(en)
*
|
2008-04-21 |
2011-08-23 |
Merck Sharp & Dohme Corp. |
CB-1 receptor modulator formulations
|
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
|
EP3239170B1
(en)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2727914A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diaryl ketoxime derivative technical field
|
|
EP2650299A1
(en)
|
2008-07-03 |
2013-10-16 |
Ratiopharm GmbH |
Crystalline salts of sitagliptin
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
US20100069637A1
(en)
*
|
2008-07-29 |
2010-03-18 |
Medichem S.A. |
CRYSTALLINE SALT FORMS OF A 5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[4,3-a]PYRAZINE DERIVATIVE
|
|
EP2319841A1
(en)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
EP2322499A4
(en)
*
|
2008-08-07 |
2011-12-21 |
Kyorin Seiyaku Kk |
PROCESS FOR PREPARING A BICYCLO [2,2,2] OCTYLAMINE DERIVATIVE
|
|
CN102186474A
(zh)
*
|
2008-08-14 |
2011-09-14 |
杏林制药株式会社 |
稳定的医药组合物
|
|
EP2326326B1
(en)
*
|
2008-08-15 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
|
|
US8476437B2
(en)
|
2008-08-27 |
2013-07-02 |
Cadila Healthcare Limited |
Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof
|
|
EP2344195A2
(en)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Combination therapy for the treatment of diabetes and related conditions
|
|
CA2738663A1
(en)
|
2008-10-03 |
2010-04-08 |
Schering Corporation |
Spiro-imidazolone derivatives as glucagon receptor antagonists
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
KR101054911B1
(ko)
*
|
2008-10-17 |
2011-08-05 |
동아제약주식회사 |
디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
|
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
EP2350010B1
(en)
|
2008-10-30 |
2014-03-26 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
|
CA2743489A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
|
EA022310B1
(ru)
|
2008-12-23 |
2015-12-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Солевые формы органического соединения
|
|
EP2381772B1
(en)
*
|
2008-12-31 |
2016-08-24 |
Chiral Quest, Inc. |
Process and intermediates for the preparation of n-acylated-4-aryl beta-amino acid derivatives
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
WO2010079433A2
(en)
*
|
2009-01-07 |
2010-07-15 |
Glenmark Pharmaceuticals, S.A. |
Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor
|
|
AU2010204144B2
(en)
|
2009-01-09 |
2012-02-16 |
Orchid Research Laboratories Ltd. |
Dipeptidyl peptidase IV inhibitors
|
|
AR075204A1
(es)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
|
|
EP2218721A1
(en)
|
2009-02-11 |
2010-08-18 |
LEK Pharmaceuticals d.d. |
Novel salts of sitagliptin
|
|
AU2010212823B2
(en)
|
2009-02-13 |
2016-01-28 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
CA2751834C
(en)
|
2009-02-13 |
2018-07-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
|
EP2223923A1
(en)
|
2009-02-25 |
2010-09-01 |
Esteve Química, S.A. |
Process for the preparation of a chiral beta aminoacid derivative and intermediates thereof
|
|
CN101824036A
(zh)
*
|
2009-03-05 |
2010-09-08 |
上海恒瑞医药有限公司 |
四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
|
|
US8598347B2
(en)
*
|
2009-03-30 |
2013-12-03 |
Dong-A Pharmaceutical. Co., Ltd |
Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate
|
|
MX344498B
(es)
|
2009-03-30 |
2016-12-19 |
Dong A St Co Ltd |
Procedimiento mejorado para preparar inhibidor de dipeptidil peptidasa-iv e intermediario.
|
|
CN101849944A
(zh)
*
|
2009-03-31 |
2010-10-06 |
江苏恒瑞医药股份有限公司 |
治疗2型糖尿病的药物组合物
|
|
WO2010122578A2
(en)
*
|
2009-04-20 |
2010-10-28 |
Msn Laboratories Limited |
Process for the preparation of sitagliptin and its intermediates
|
|
US8846916B2
(en)
|
2009-05-11 |
2014-09-30 |
Generics [Uk] Limited |
Sitagliptin synthesis
|
|
CN101899047B
(zh)
*
|
2009-05-26 |
2016-01-20 |
盛世泰科生物医药技术(苏州)有限公司 |
作为二肽基肽酶抑制剂用于治疗或预防糖尿病的β-氨基四氢吡嗪、四氢嘧啶和四氢吡啶
|
|
CN101899048B
(zh)
*
|
2009-05-27 |
2013-04-17 |
上海恒瑞医药有限公司 |
(R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
|
|
WO2010144664A1
(en)
|
2009-06-12 |
2010-12-16 |
Schering Corporation |
Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
|
|
IT1395596B1
(it)
*
|
2009-06-30 |
2012-10-16 |
Dipharma Francis Srl |
Procedimento per la preparazione di sitagliptin
|
|
JO3156B1
(ar)
|
2009-07-09 |
2017-09-20 |
Novartis Ag |
ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
|
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
|
US20120220567A1
(en)
|
2009-07-23 |
2012-08-30 |
Shipps Jr Gerald W |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
US20120189611A1
(en)
|
2009-08-03 |
2012-07-26 |
Kaneka Corporation |
Dipeptidyl peptidase-4 inhibitor
|
|
JP5753848B2
(ja)
*
|
2009-08-13 |
2015-07-22 |
サンド・アクチエンゲゼルシヤフト |
７−［（３Ｒ）−３−アミノ−１−オキソ−４−（２，４，５−トリフルオロフェニル）ブチル］−５，６，７，８−テトラヒドロ−３−（トリフルオロメチル）−１，２，４−トリアゾロ［４，３−ａ］ピラジンの結晶性化合物
|
|
EP2464228B1
(en)
|
2009-08-13 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
|
JP5734981B2
(ja)
|
2009-09-02 |
2015-06-17 |
メルク・シャープ・エンド・ドーム・コーポレイション |
糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
|
|
PL2475428T3
(pl)
|
2009-09-11 |
2015-12-31 |
Probiodrug Ag |
Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
|
|
EP2295083A1
(de)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
|
|
CN102030683B
(zh)
*
|
2009-09-27 |
2013-07-31 |
浙江九洲药业股份有限公司 |
西他列汀中间体及其制备方法和用途
|
|
EP2308847B1
(en)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
|
|
EP2501685A1
(en)
|
2009-11-16 |
2012-09-26 |
Mellitech |
[1,5]-diazocin derivatives
|
|
CN102753161A
(zh)
|
2009-11-27 |
2012-10-24 |
贝林格尔.英格海姆国际有限公司 |
基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
|
|
WO2011079778A1
(en)
|
2009-12-30 |
2011-07-07 |
China Shanghai Fochon Pharmaceutical Co Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
|
KR101156587B1
(ko)
|
2010-02-19 |
2012-06-20 |
한미사이언스 주식회사 |
시타글립틴의 제조방법 및 이에 사용되는 아민염 중간체
|
|
EP2538783B1
(en)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
EP2542549B1
(en)
|
2010-03-03 |
2016-05-11 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
|
EP2545047B9
(en)
|
2010-03-10 |
2015-06-10 |
Probiodrug AG |
Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
|
|
CZ303113B6
(cs)
|
2010-03-16 |
2012-04-11 |
Zentiva, K.S. |
Zpusob prípravy sitagliptinu
|
|
US20130109703A1
(en)
|
2010-03-18 |
2013-05-02 |
Boehringer Ingelheim International Gmbh |
Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
|
|
EP2547682A1
(en)
|
2010-03-31 |
2013-01-23 |
Teva Pharmaceutical Industries Ltd. |
Solid state forms of sitagliptin salts
|
|
CA2795514A1
(en)
*
|
2010-04-05 |
2011-10-13 |
Cadila Pharmaceuticals Limited |
Novel hypoglycemic compounds
|
|
WO2011127051A1
(en)
|
2010-04-06 |
2011-10-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
|
ES2629624T3
(es)
|
2010-04-28 |
2017-08-11 |
Sun Pharmaceutical Industries Limited |
Proceso para la preparación de derivados quirales de la beta amino carboxamida
|
|
NZ602921A
(en)
|
2010-05-05 |
2016-01-29 |
Boehringer Ingelheim Int |
Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
|
|
EP2571876B1
(en)
|
2010-05-21 |
2016-09-07 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
CN102260265B
(zh)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
|
|
EP2576563B1
(en)
|
2010-06-04 |
2016-05-11 |
LEK Pharmaceuticals d.d. |
A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS
|
|
EP2392575A1
(en)
|
2010-06-04 |
2011-12-07 |
LEK Pharmaceuticals d.d. |
A novel synthetic approach to ß-aminobutyryl substituted compounds
|
|
EP2397141A1
(en)
|
2010-06-16 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
Process for the synthesis of beta-amino acids and derivatives thereof
|
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
|
EP2407469A1
(en)
|
2010-07-13 |
2012-01-18 |
Chemo Ibérica, S.A. |
Salt of sitagliptin
|
|
SG187226A1
(en)
|
2010-07-28 |
2013-03-28 |
Neuralstem Inc |
Methods for treating and/or reversing neurodegenerative diseases and/or disorders
|
|
EP2423178A1
(en)
|
2010-07-28 |
2012-02-29 |
Chemo Ibérica, S.A. |
Process for the production of sitagliptin
|
|
EP2418196A1
(en)
*
|
2010-07-29 |
2012-02-15 |
IMTM GmbH |
Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
|
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
|
WO2012027331A1
(en)
|
2010-08-27 |
2012-03-01 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
|
US20130158265A1
(en)
|
2010-08-27 |
2013-06-20 |
Dhananjay Govind Sathe |
Sitagliptin, salts and polymorphs thereof
|
|
WO2012035549A2
(en)
|
2010-09-13 |
2012-03-22 |
Panacea Biotec Ltd |
An improved process for the synthesis of beta amino acid derivatives
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US20130289276A1
(en)
*
|
2010-10-08 |
2013-10-31 |
Cadila Healthcare Limited |
Process for preparing an intermediate of sitagliptin via enzymatic conversion
|
|
WO2012049566A1
(en)
|
2010-10-14 |
2012-04-19 |
Japan Tobacco Inc. |
Combination therapy for use in treating diabetes
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
CN102485718B
(zh)
|
2010-12-03 |
2014-03-26 |
浙江海翔药业股份有限公司 |
西他列汀的中间体及其制备方法
|
|
EP2648517B1
(en)
|
2010-12-06 |
2015-08-05 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
|
|
WO2012076973A2
(en)
|
2010-12-09 |
2012-06-14 |
Aurobindo Pharma Limited |
Novel salts of dipeptidyl peptidase iv inhibitor
|
|
TWI494313B
(zh)
*
|
2010-12-29 |
2015-08-01 |
Jiangsu Hengrui Medicine Co |
治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
|
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
|
US11974971B2
(en)
|
2011-01-07 |
2024-05-07 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
|
CA2823397C
(en)
*
|
2011-01-07 |
2020-03-10 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
|
KR101290029B1
(ko)
|
2011-01-20 |
2013-07-30 |
에스티팜 주식회사 |
시타글립틴의 중간체 제조방법
|
|
SI2670486T1
(sl)
|
2011-01-31 |
2016-09-30 |
Cadila Healthcare Limited Zydus Tower Satellite Cross Roads |
Zdravljenje lipodistrofije
|
|
JP5728099B2
(ja)
|
2011-02-25 |
2015-06-03 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
|
|
EA201391254A1
(ru)
|
2011-03-01 |
2014-02-28 |
Синерджи Фармасьютикалз Инк. |
Способ получения агонистов гуанилатциклазы c
|
|
DK2681220T3
(en)
*
|
2011-03-03 |
2015-11-30 |
Cadila Healthcare Ltd |
PRESENT UNKNOWN SALTS OF DPP-IV INHIBITOR
|
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
|
EA029539B8
(ru)
|
2011-03-29 |
2018-06-29 |
Крка, Товарна Здравил, Д.Д., Ново Место |
Фармацевтическая композиция ситаглиптина
|
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
EP2508506A1
(en)
|
2011-04-08 |
2012-10-10 |
LEK Pharmaceuticals d.d. |
Preparation of sitagliptin intermediates
|
|
JP6047144B2
(ja)
|
2011-04-08 |
2016-12-21 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
置換シクロプロピル化合物、このような化合物を含有する組成物および処置方法
|
|
KR101369584B1
(ko)
|
2011-04-19 |
2014-03-06 |
일양약품주식회사 |
페닐-이속사졸 유도체 및 그의 제조방법
|
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
CN102757431B
(zh)
*
|
2011-04-24 |
2016-03-30 |
浙江华海药业股份有限公司 |
一种合成西他列汀的新方法
|
|
ITMI20110765A1
(it)
|
2011-05-05 |
2012-11-06 |
Chemo Iberica Sa |
Processo per la produzione di sitagliptina
|
|
US8524936B2
(en)
|
2011-05-18 |
2013-09-03 |
Milan Soukup |
Manufacturing process for sitagliptin from L-aspartic acid
|
|
US9359385B2
(en)
*
|
2011-05-27 |
2016-06-07 |
Lek Pharmaceuticals D.D. |
Preparation of sitagliptin intermediates
|
|
EP2527320A1
(en)
|
2011-05-27 |
2012-11-28 |
LEK Pharmaceuticals d.d. |
Preparation of Sitagliptin Intermediates
|
|
JP2014518890A
(ja)
|
2011-06-02 |
2014-08-07 |
インターベット インターナショナル ベー． フェー． |
イミダゾール誘導体
|
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
AR086675A1
(es)
*
|
2011-06-14 |
2014-01-15 |
Merck Sharp & Dohme |
Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
|
|
US9006228B2
(en)
|
2011-06-16 |
2015-04-14 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
|
KR20140034861A
(ko)
|
2011-06-29 |
2014-03-20 |
머크 샤프 앤드 돔 코포레이션 |
디펩티딜 펩티다제-iv 억제제의 신규한 결정질 형태
|
|
AU2012277373A1
(en)
|
2011-06-29 |
2014-01-30 |
Sun Pharmaceutical Industries Limited |
Solid dispersions of sitagliptin and processes for their preparation
|
|
EP2726483A1
(en)
|
2011-06-30 |
2014-05-07 |
Ranbaxy Laboratories Limited |
Novel salts of sitagliptin
|
|
EP2729468A4
(en)
|
2011-07-05 |
2015-03-18 |
Merck Sharp & Dohme |
Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
|
|
US8883800B2
(en)
|
2011-07-15 |
2014-11-11 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
|
EA024688B1
(ru)
*
|
2011-07-27 |
2016-10-31 |
ФАРМА ДжРС, Д.О.О. |
Способ получения ситаглиптина и его фармацевтически приемлемых солей
|
|
US20140302150A1
(en)
|
2011-09-07 |
2014-10-09 |
Umit Cifter |
Dpp-iv inhibitor formulations
|
|
WO2013048916A1
(en)
|
2011-09-30 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
|
PL2578208T3
(pl)
|
2011-10-06 |
2014-10-31 |
Sanovel Ilac Sanayi Ve Ticaret As |
Stałe formulacje dawkowane inhibitora DPP-IV
|
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
CN106905321A
(zh)
*
|
2011-10-14 |
2017-06-30 |
劳乐斯实验室私营有限公司 |
新的西他列汀盐、其制备方法及其药物组合物
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
WO2013062838A1
(en)
|
2011-10-24 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as gpr119 agonists
|
|
CN102603749B
(zh)
*
|
2011-10-27 |
2017-02-08 |
浙江华海药业股份有限公司 |
一种西他列汀中间体的合成方法
|
|
WO2013065066A1
(en)
|
2011-11-02 |
2013-05-10 |
Cadila Healthcare Limited |
Processes for preparing 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [l,2,41-triazolo[43-a]pyrazin-7(8h)-yl]-l-(2,4,5- trifluorophenyl)butan-2-amine
|
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
|
CA2855009C
(en)
|
2011-11-15 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
|
EP2788352A1
(en)
|
2011-12-08 |
2014-10-15 |
Ranbaxy Laboratories Limited |
Amorphous form of sitagliptin salts
|
|
ES2832773T3
(es)
|
2012-01-06 |
2021-06-11 |
Anji Pharma Us Llc |
Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
|
|
CN104349773A
(zh)
|
2012-01-06 |
2015-02-11 |
埃尔舍利克斯治疗公司 |
用于治疗代谢性病症的组合物和方法
|
|
EP2615080A1
(en)
|
2012-01-12 |
2013-07-17 |
LEK Pharmaceuticals d.d. |
Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
|
|
US9073930B2
(en)
|
2012-02-17 |
2015-07-07 |
Merck Sharp & Dohme |
Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
|
ES2421956B1
(es)
|
2012-03-02 |
2014-09-29 |
Moehs Ibérica S.L. |
Nueva forma cristalina de sulfato de sitagliptina
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
CN104411710A
(zh)
|
2012-04-16 |
2015-03-11 |
卡内克制药公司 |
作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
|
|
TWI469785B
(zh)
|
2012-04-25 |
2015-01-21 |
Inovobiologic Inc |
用於治療代謝性疾病之膳食纖維組成物
|
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
EP2674432A1
(en)
|
2012-06-14 |
2013-12-18 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of ß aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds
|
|
US9315508B2
(en)
|
2012-07-23 |
2016-04-19 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-IV inhibitors
|
|
EP2874626A4
(en)
|
2012-07-23 |
2016-03-23 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
|
CA2880901A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
AU2013301410A1
(en)
|
2012-08-08 |
2015-02-26 |
Cipla Limited |
Process for the preparation of sitagliptin and intermediate compounds
|
|
CN102898387B
(zh)
*
|
2012-09-26 |
2015-01-07 |
浙江工业大学 |
管道化连续生产n-[(2z)-哌嗪-2-亚基]-2,2,2-三氟乙酰肼的方法
|
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
|
CN103788070B
(zh)
*
|
2012-10-26 |
2017-10-20 |
南京华威医药科技开发有限公司 |
Dpp‑4抑制剂类多聚物
|
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
|
CZ306115B6
(cs)
|
2012-12-04 |
2016-08-10 |
Zentiva, K.S. |
Způsob přípravy derivátů kyseliny 3-amino-4-(2,4,5-trifluorfenyl)-butanové
|
|
CN103319487B
(zh)
*
|
2013-01-10 |
2015-04-01 |
药源药物化学（上海）有限公司 |
西格列汀的制备方法及其中间体
|
|
EP2769712A1
(en)
|
2013-02-21 |
2014-08-27 |
Siegfried International AG |
Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
|
|
CN104003992B
(zh)
*
|
2013-02-22 |
2016-09-28 |
成都先导药物开发有限公司 |
一种抑制dpp-iv的化合物及其中间体
|
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
IN2013MU00916A
(pl)
|
2013-03-20 |
2015-06-26 |
Cadila Healthcare Ltd |
|
|
MX346943B
(es)
|
2013-04-22 |
2017-04-06 |
Cadila Healthcare Ltd |
Una nueva composición para esteatosis hepática no alcohólica (nafld).
|
|
EP3004053B1
(en)
|
2013-05-30 |
2021-03-24 |
Cadila Healthcare Limited |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
|
ES2981866T3
(es)
|
2013-06-05 |
2024-10-10 |
Bausch Health Ireland Ltd |
Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos
|
|
WO2015001568A2
(en)
*
|
2013-07-01 |
2015-01-08 |
Laurus Labs Private Limited |
Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
|
|
TW201636015A
(zh)
|
2013-07-05 |
2016-10-16 |
卡地拉保健有限公司 |
協同性組成物
|
|
IN2013MU02470A
(pl)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
|
IN2013MU02905A
(pl)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
CZ2013842A3
(cs)
|
2013-11-01 |
2015-05-13 |
Zentiva, K.S. |
Stabilní polymorf soli (2R)-4-oxo-4-[3-(trifluorometyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorofenyl)butan-2-aminu s kyselinou L-vinnou
|
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
|
CN103626775B
(zh)
*
|
2013-12-02 |
2015-05-20 |
南京华威医药科技开发有限公司 |
具有二嗪结构的dpp-4抑制剂
|
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
|
IN2014MU00212A
(pl)
|
2014-01-21 |
2015-08-28 |
Cadila Healthcare Ltd |
|
|
WO2015112465A1
(en)
|
2014-01-24 |
2015-07-30 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as mgat2 inhibitors
|
|
IN2014MU00651A
(pl)
|
2014-02-25 |
2015-10-23 |
Cadila Healthcare Ltd |
|
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
|
WO2015145333A1
(en)
|
2014-03-26 |
2015-10-01 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of sitagliptin and its intermediate
|
|
JP6523328B2
(ja)
|
2014-04-17 |
2019-05-29 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
タンニン酸シタグリプチン複合体
|
|
WO2015162506A1
(en)
|
2014-04-21 |
2015-10-29 |
Suven Life Sciences Limited |
Process for the preparation of sitagliptin and novel intermediates
|
|
WO2015170340A2
(en)
*
|
2014-05-06 |
2015-11-12 |
Laurus Labs Private Limited |
Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
|
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US9862725B2
(en)
|
2014-07-21 |
2018-01-09 |
Merck Sharp & Dohme Corp. |
Process for preparing chiral dipeptidyl peptidase-IV inhibitors
|
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2016022448A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
CN104140430B
(zh)
*
|
2014-08-08 |
2016-07-13 |
广东东阳光药业有限公司 |
一种异构体的消旋方法
|
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
|
WO2016046679A1
(en)
*
|
2014-09-28 |
2016-03-31 |
Mohan M Alapati |
Compositions and methods for the treatment of diabetes and pre-diabetes
|
|
WO2016064737A1
(en)
|
2014-10-20 |
2016-04-28 |
Neuralstem, Inc. |
Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
|
|
WO2016112075A1
(en)
|
2015-01-06 |
2016-07-14 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
CN107428761B
(zh)
|
2015-01-08 |
2019-11-05 |
李氏制药有限公司 |
制备二肽基肽酶-4(dpp-4)抑制剂的方法
|
|
CZ27898U1
(cs)
|
2015-01-13 |
2015-03-02 |
Zentiva, K.S. |
Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
|
|
CZ27930U1
(cs)
|
2015-01-13 |
2015-03-10 |
Zentiva, K.S. |
Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
|
|
SG11201707276PA
(en)
|
2015-03-09 |
2017-10-30 |
Intekrin Therapeutics Inc |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
|
MX2017013222A
(es)
*
|
2015-04-15 |
2018-02-15 |
Valent Biosciences Llc |
Derivados de acido (s)-2'-vinil-abscisico.
|
|
KR101772898B1
(ko)
|
2015-06-11 |
2017-08-31 |
동방에프티엘(주) |
시타글립틴의 개선된 제조방법
|
|
KR101709127B1
(ko)
|
2015-06-16 |
2017-02-22 |
경동제약 주식회사 |
Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
|
|
PT3310760T
(pt)
|
2015-06-22 |
2022-11-10 |
Arena Pharm Inc |
Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
|
|
CN105017260B
(zh)
*
|
2015-07-30 |
2017-04-19 |
新发药业有限公司 |
一种西他列汀中间体三唑并吡嗪衍生物的制备方法
|
|
US11000521B2
(en)
|
2015-08-03 |
2021-05-11 |
Institut Pasteur |
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
|
|
CN108368494A
(zh)
*
|
2015-09-09 |
2018-08-03 |
沃伦·C·刘 |
新型fyn激酶抑制剂的方法、组合物以及用途
|
|
KR20170036288A
(ko)
|
2015-09-24 |
2017-04-03 |
주식회사 종근당 |
시타글립틴의 신규염 및 이의 제조방법
|
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
|
EP3159343B1
(en)
*
|
2015-10-22 |
2017-07-19 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Improved process for the preparation of triazole and salt thereof
|
|
US20190382363A1
(en)
|
2015-11-30 |
2019-12-19 |
Merck Sharp & Dohme Corp. |
Aryl sulfonamides as blt1 antagonists
|
|
EP3383869B1
(en)
|
2015-11-30 |
2023-06-28 |
Merck Sharp & Dohme LLC |
Aryl sulfonamides as blt1 antagonists
|
|
KR20220080015A
(ko)
|
2016-04-22 |
2022-06-14 |
악셀레론 파마 인코포레이티드 |
Alk7 결합 단백질 및 이들의 용도
|
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
|
EP4233840A3
(en)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
|
WO2018034918A1
(en)
|
2016-08-15 |
2018-02-22 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
|
WO2018034917A1
(en)
|
2016-08-15 |
2018-02-22 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
|
CN106124667B
(zh)
*
|
2016-08-29 |
2018-07-31 |
上海应用技术学院 |
一种分离测定西格列汀有关物质的方法
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
MX2016016260A
(es)
|
2016-12-08 |
2018-06-07 |
Alparis Sa De Cv |
Nuevas formas solidas de sitagliptina.
|
|
ES2894261T3
(es)
|
2016-12-09 |
2022-02-14 |
Cadila Healthcare Ltd |
Tratamiento de la colangitis biliar primaria
|
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
US11197949B2
(en)
|
2017-01-19 |
2021-12-14 |
Medtronic Minimed, Inc. |
Medication infusion components and systems
|
|
US10047094B1
(en)
|
2017-02-10 |
2018-08-14 |
F.I.S.—Fabbrica Italiana Sintetici S.p.A. |
Process for the preparation of triazole and salt thereof
|
|
MX2019009841A
(es)
|
2017-02-16 |
2020-01-30 |
Arena Pharm Inc |
Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
|
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
|
KR20200036808A
(ko)
|
2017-04-03 |
2020-04-07 |
코히러스 바이오사이언시스, 인크. |
진행성 핵상 마비 치료를 위한 PPARγ 작용제
|
|
WO2018198021A1
(en)
|
2017-04-24 |
2018-11-01 |
Novartis Ag |
Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
|
|
US11096890B2
(en)
|
2017-09-29 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
Chewable dosage forms containing sitagliptin and metformin
|
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
|
KR20190060235A
(ko)
|
2017-11-24 |
2019-06-03 |
제일약품주식회사 |
시타글립틴 캄실산염의 제조방법
|
|
TR201722603A2
(tr)
|
2017-12-28 |
2019-07-22 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
|
|
CN108586346B
(zh)
|
2018-05-10 |
2019-10-01 |
北京富盛嘉华医药科技有限公司 |
一种生物催化合成西他列汀及其中间体的方法
|
|
CN112601516A
(zh)
|
2018-06-06 |
2021-04-02 |
艾尼纳制药公司 |
治疗与s1p1受体相关的病况的方法
|
|
TW202045476A
(zh)
|
2019-02-13 |
2020-12-16 |
美商默沙東藥廠 |
5-烷基吡咯啶食慾素受體促效劑
|
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
WO2021076066A1
(en)
|
2019-10-14 |
2021-04-22 |
Santa Farma İlaç Sanayi̇ A.Ş. |
Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
|
|
KR20210057603A
(ko)
|
2019-11-12 |
2021-05-21 |
제이투에이치바이오텍 (주) |
시타글립틴의 제조방법
|
|
MX2023001840A
(es)
|
2020-08-18 |
2023-03-13 |
Merck Sharp & Dohme Llc |
Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
|
|
CN116368140A
(zh)
*
|
2020-09-10 |
2023-06-30 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
KR102589305B1
(ko)
|
2021-04-22 |
2023-10-16 |
주식회사 메디켐코리아 |
시타글립틴 인산염의 개선된 제조방법
|
|
CN113979896A
(zh)
*
|
2021-11-18 |
2022-01-28 |
浙江永太手心医药科技有限公司 |
一种西格列汀杂质i及其制备方法
|
|
EP4469459A1
(en)
|
2022-01-24 |
2024-12-04 |
Zaklady Farmaceutyczne Polpharma S.A. |
Process for preparing crystalline sitagliptin hydrochloride monohydrate
|
|
WO2024086263A1
(en)
|
2022-10-21 |
2024-04-25 |
Merck Sharp & Dohme Llc |
Compositions of a dipeptidyl peptidase-iv inhibitor and an antioxidant
|
|
WO2024121301A1
(en)
|
2022-12-09 |
2024-06-13 |
Krka, D.D., Novo Mesto |
Process for the preparation of sitagliptin
|
|
CN116064457A
(zh)
|
2022-12-16 |
2023-05-05 |
浙江工业大学 |
一种ω-转氨酶突变体及其应用
|
|
EP4431087A1
(en)
|
2023-03-14 |
2024-09-18 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet of sitagliptin or a pharmaceutically acceptable salt thereof
|